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Introduction
In most countries world-wide, except for Japan, squamous
cell carcinoma of the esophagus (scc) is usually diagnosed
in advanced stage (III°, IV°) of the disease. This results in
limited curative options due to low resectability/opera-
bility rates and poor prognosis for patients (pts) with
T3/T4 N0-1 scc and usually directs treatment intention to
a palliative setting. The main objectives of treatment are,
therefore, local control and palliation of dysphagia.
Based on the positive results from the Herskovic
trial [1], as well as on other randomised studies [2-4]
concurrent chemotherapy and radiotherapy became
recognised as effective treatment modalities for loco-
regionally advanced scc. However, despite multiple efforts
for improving results of conservative treatment, definitive
chemo-radiotherapy is still associated with a high rate
(about 50%) of locally persistent or recurrent disease [5-
8].
We have undertaken this study with the aim of
evaluating immediate and long-term effects of combined
chemo-radiotherapy in loco-regionally advanced scc in
terms of dysphagia relief, tumour response, pain control
and weight gain.
Material
From June 1997 to October 2000, 57 pts with histologically
proven T3/T4, N0-1 scc underwent conservative treatment with
radiotherapy or radio-chemotherapy at The Madame Sklo-
dowska-Curie Memorial Cancer Centre and Institute of Onco-
logy in Warsaw.
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I n t r o d u c t i o n. Squamous cell carcinoma of the esophagus (scc) is usually diagnosed in an advanced stage resulting in
limited curative options. The aim was to evaluate immediate and long-term effects of combined chemo-radiotherapy of
loco-regionally advanced scc in terms of dysphagia relief and tumour response.
M a t e r i a l  a n d  m e t h o d s. Between 1997 and 2000, 35 pts with scc completed full definitive non-surgical treatment.
Men – 31, women – 4; mean age: 51. Tumour stage: T4 – 5, T3 – 30, node stage: N0 – 8, N1 – 27; dysphagia at presentation:
WHO III° – 17%, II° – 46%, I° – 37%. Irradiation: conventional fractionation to a dose of 56-60 Gy to tumour, 54-60 Gy to
enlarged lymph nodes, 40-44 Gy electively to regional lymph nodes in combination with 2 courses of i.v. chemotherapy: 
5-fluorouracil: 800 mg/m2/24h (day: 1-4, 22-25), cisplatin: 80 mg/m2 (day: 1, 22) followed by HDR brachytherapy boost using
192Ir – 6 Gy after a one week interval. During follow-up the patients were scored according to the swallowing function,
weight change and pain control. Tumour regression and late radiotherapy side effects were observed.
R e s u l t s. Initial improvement in dysphagia occurred in 20/35 patients (57%) during treatment. Durable improvement at 
1-year was evidenced in 19/35 (54%) pts. 31% were dysphagia-free at 1 year. Average duration of dysphagia improvement was
11 months. Only patients with marked improvement in the swallowing function documented during treatment were able to
maintain this function for a longer time. We achieved an overall response rate to treatment of 52%. CR (local control) was
noted in 26% of pts and local progression (PD) in 34% at 12 months. The median time to tumour progression was 5.4 months.
Systemic failure was noted in 20% of patients. The median time to metastases was 8 months and median survival – 12.5
months with a 1-year observed survival of 54%, 2-year– 31% and 3-year – 23%.
C o n c l u s i o n s. 1. Primary concurrent chemo-radiotherapy for advanced T3/T4 N0-1 scc of the oesophagus seems to be
a reasonable modality to control short- and long-term dysphagia and pain. 2. The rate and degree of the initial improvement
of the swallowing function is a good prognostic tool for assessing the long-term swallowing status. 3. Relatively low local control
rate of 26%, due to advanced stage of the disease in our patients, indicates the need for further evaluation of a more efficient
treatment modality in this tumour with poor prognostis.
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These patients were not candidates for primary surgery
due to either the localisation of the tumour in the cervical
oesophagus or advanced local disease or potential high morbidity
due to pre-existing general health conditions. A few patients
also refused offered surgery. 35 patients were treated with
a phase II study protocol of combined radio and chemotherapy
and managed to complete the full treatment course. The
remaining 22 patients were ultimately treated palliativly due to
intercurrent diseases or deterioration of the performance status
during treatment.
The primary and secondary aims of the study were:
feasibility of the proposed combined treatment, local control,
overall survival, disease free survival, patterns of failure as well
as improvement in swallowing function and it’s durability. We
finally evaluated 35 patients treated according to the protocol.
Mean age was 51 years, range: 21 – 73 years. Median weight
loss before treatment was 6.1 kg (range: 0-17 kg).
Patient characteristics are presented in Table I.
Table I. Patient characteristics
Number %
Men 31/35 88.5%
Women 4/35 11.5%
Tumour stage:
T3 30/35 86%
T4 5/ 35 14%
Node stage:
N0 8/35 23%
N1 27/35 77%
M1LYM 7/35 20%
Tumour site:
upper 7/35 20%
middle 13/35 37%
lower 15/35 43%
Performance status WHO:
1° 31/35 89%
2° 4/35 11%
Dysphagia at presentation (WHO):
1° 13/35 37%
2° 16/35 46%
3° 6/35 17%
Methods
The patients were irradiated using conventional fractionation
to a dose of 56-60 Gy delivered to the tumour, 54-60 Gy
selectively delivered to enlarged lymph nodes and 40-44 Gy
electively delivered to regional lymph nodes. Radiotherapy
was combined with 2 courses of iv. infusion chemotherapy
consisting of: 5-fluorouracil 800 mg/m2/24h (day: 1-4, 22-25),
cisplatin 80 mg/m2 (day: 1 and 22) and followed by a high dose
rate brachytherapy boost using 192Ir – single application of 6
Gy after one week interval.
During follow-up patients were scored according to the
swallowing function. Weight change and pain control were noted.
Esophagogram, gastroscopy and CT scan were performed
to estimate tumour regression as well as late radiotherapy
effects.
Results
S w a l l o w i n g  s t a t u s
Pre-treatment swallowing function of the patients is
shown in Table II. Dysphagia to solids is scored as mild
degree – 1°, difficulties in swallowing semisolids means
moderate dysphagia – 2°, dysphagia to liquids is of severe
degree – 3°. All analysed patients presented with
dysphagia and in 17% of cases it was of severe degree.
The pre-treatment and the post-treatment swallowing
function was determined using this scoring system and is
shown in Table II.
Table II. Dysphagia scale used in assessing swallowing ability 
in treated patients.
Status before and after treatment
Swallowing scale Pre-treatment Maximal 
status improvement status
No./(%) No./(%)
No dysphagia – 0° 0 11 (31%)
Mild dysphagia – 1° 13 (37%) 8 (23%)
Moderate dysphagia – 2° 16 (46%) 9 (26%)
Severe dysphagia – 3° 6 (17%) 7 (20%)
A change in swallowing status was defined as
increase or decrease in the swallowing score by one or
more grades from the initial status. Initial improvement in
dysphagia occurred in 20/35 patients (57%) during the 6
weeks of combined treatment. No change was noted in 8
patients, deterioration in swallowing function in 7 patients
(Figure 1.). Further downstaging of dysphagia within 1-7
months after radiotherapy was observed in 14/35 patients
(40%). Durable improvement at 1-year follow up was
evidenced in 19/35 – 54% of patients. 31% of all the
patients treated were dysphagia-free at 1 year (65% of the
1-year survivors). Minimal duration of dysphagia
improvement was 23 days, maximal – 44.7 months;
average – 11 months.
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Figure 1. Change in the swallowing status defined as an increase or
decrease in the swallowing score by one or more grade from the pre-
treatment swallowing score. Overall improvement of the swallowing
status was observed in 20/35 (57%) of patients during treatment. 19/35
(54%) of patients maintained improved swallowing status at one year
Only patients with initial marked improvement in
the swallowing function during treatment were able to
maintain this function for a longer period of time. In
a retrospective analysis the overall number of patients
with changes in the swallowing score by one or more units
was determined and it is shown on Figure 2. Further
change in the swallowing function was evaluated during
follow-up at monthly intervals.
Assessment of long-term swallowing function in
patients with advanced disease is limited by their relatively
short survival. That is why the observation period in
patients with progression after treatment was limited to
one year. Figure 3 shows the results of a one-year follow-
up of thr dysphagia stage in 12 patients out of 35 (34%)
who presented with deterioration in the swallowing status.
Tu m o u r  c o n t r o l
All follow-up assessments were performed regularly every
1 month for a year then at 3-month intervals.
The tumour response was assessed by radiographic
criteria (barium contrast, CT) and endoscopy, with biopsy
if possible. Complete regression (CR) was recognised if
no evidence of tumour presence could be seen during
barium contrast examination and endoscopy. Partial
regression (PR) was defined as a decrease by more than
50% of maximum tumour size. Stable disease (SD) was
regarded if there was a decrease in the tumour mass by
less than 50% or an increase of not more than 25%. Local
progression (progression disease PD) was recognised if
progression by more than 25% of the tumour size was
documented either within the primary tumour or
local/regional nodes. Systemic relapse (PD) was defined
as any evidence of distant metastases.
Overall response rate to treatment was 52%, CR
(local control) was seen in 26% of patients at one year
(Table III). Local progression (PD) after treatment was
observed in 17% of patients at 6 months, and in 34% at
12 months. Median time to tumour progression was 5.4
months. Systemic failure was noted in 20% of patients.
Median time to metastases was 8 months.
Table III. Treatment result at one year assessed by endoscopic
and radiographic criteria
Outcome Number of patients Percent
complete regression (CR) 9/35 26%
partial regression (PR) 9/35 26%
no change (SD) 5/35 14%
local progression (PD) 12/35 34%
systemic relapse (PD) 7/35 20%
To x i c i t y
Acute complications
The 35 patients of the analysed group were able to
tolerate full doses of radiation and chemotherapy
according to the protocol. The tolerance of the combined
modality therapy was good. There were no toxic deaths.
Severe oesophagitis (Grade 3 according to CTC criteria)
occurred in 3% of patients, moderate (Grade 2) in 31%.
They did not require interruption or delay in treatment
and the observed complications responded well to
medical treatment. Severe haematological toxicity was
noted in 17% of patients and in this group treatment had
to be temporarily withheld.
Average weight loss recorded during treatment was
1.5 kg.
Late complications were of paramount importance in
these patients since they influenced their ability to
swallow. The total complication rate at one year was 25%.
4/35 (11%) patients developed moderate or severe
strictures requiring dilatation, 5/35 (14%) patients
developed a tracheo-esophageal fistula requiring endo-
prosthesis placement. All but one case of fistula were
treatment-related (in tumours initially staged as T3).
The weight change correlated with the swallowing
function and tumour progression. Average weight gain
at follow-up was 2.8 kg (range: -4 – +10 kg).
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Figure 2. The distribution of patients by dysphagia score. 31% of
patients (all after immediate marked improvement) had complete
restoration of their ability to swallow solids after therapy
Figure 3. Subjective and objective deterioration of swallowing as
a function of time. Estimated each month following completion of
treatment. 12/35 of patients (34%) presented growing difficulties in
swallowing associated with tumour progression
Treatment resulted in good pain control. Only 5 out
of 35 patients (14%) required opioid analgesics during
follow-up after treatment.
S u r v i v a l
For the total group of 35 patients median survival was
12.5 months, 1-year observed survival was 54%, 2-year –
31%, 3-year observed survival achieved 23%.
Discussion
Advanced T3/T4, N0-1 oesophageal scc is inevitably
associated with poor prognosis and still constitutes
a challenge for both surgeons and oncologists. Patients
presenting with this disease, who are unfit for primary
surgery, are referred for conservative multimodality
treatment schedules. This is common clinical practice
supported by the results of several clinical trials [1, 6, 7, 9,
10]. In fact, as far as surgery is concerned, only few
patients are good candidates for such anapproach.
Therefore, in most cases definitive conservative treatment
ends up with a generally palliative effect due to loco-
regional treatment failure. Even in randomised trials of
concurrent chemo-radiotherapy [3, 5, 8] the rate of local
failure reached 50%. Effective delivery of an adequately
high total dose of irradiation is complicated by anatomic
constrains, as well as by the co-morbidity of patients with
this disease. Attempts to achieve effective local control
and long-term survival with combined treatment (eg.
surgery plus chemo-radiotherapy) are limited to stage I
and II of the disease.
The goals of conservative management in palliative
setting are: relief of pain, maintenance of oral food intake,
elimination of reflux and regurgitation, prevention of
aspiration. The main goals of definitive treatment with
combined radiotherapy and chemotherapy are: long term
local control and improved overall and disease-free
survival.
In our study patients were irradiated to a 60 Gy total
dose by external beam radiotherapy with concurrent
chemotherapy and a 6 Gy intraluminal brachytherapy
boost. The presented combined regime was feasible and
in patients who had completed the full treatment course
provided improvement of dysphagia in 54%, with long
term local control of cancer in 26%.
In order to enhance the local control rate for
advanced cancer a combination of radiotherapy and
chemotherapy with an HDR brachytherapy boost was
applied. This treatment strategy seemed promising with
manageable toxicity and a treatment-related acute
complication rate of 4-8% [11-13]. However, in our study
the contribution of the brachytherapy boost to the long-
term tumour regression is ambiguous. Also the rate of
late complications is relatively high – 12% of treatment
related fistulae discourages the further use of the
radiotherapy boost. Other studies [10, 14, 15] have
reported a similar fistula rate after combined treatment,
suggesting a cautious approach to the brachytherapy
boost after high dose external irradiation.
The presented treatment schedule provides prompt
and substantial improvement in swallowing in most
patients treated for oesophageal cancer. However, tumour
regression during and after treatment, manifested
subjectively as marked improvement in the swallowing
function was, in most cases, not enough to provide long-
term local control of tumour growth. Clinical predictors of
good response to chemo-radiotherapy were immediate
dysphagia improvement together with objective im-
provement barium contrast radiological results obtained
at the end of the radiotherapy course.
The local recurrence rate after non-surgical
treatment of oesophageal cancer has been reported to
be between 40%-60% [1, 7]. The local failure rate in our
study was 48% at one year. Since most of the failures
occur during the first year [5, 14, 16] this seems to be
a reasonably good result.
Complete responders after conservative treatment
can’t be accurately identified by clinical methods. That is
why only long-term survivors could be regarded as cured
from cancer. Only in their case the maintenance of good
swallowing function could become a simplified indicator
of local control. As it has already been stated by other
authors [17] the rapid restoration of the swallowing status
(during treatment) is of important prognostic value for
durable tumour control in these patients.
We have performed a retrospective survival analysis
of the treated patients. Median survival for the entire
group was 12.5 months with a 12-, 24- and 36-month
survival rate of 54%, 31% and 23% respectively.
Literature data show similar results. 20% of patients
who had received combined modality therapy in the
Herscovic trial were alive at 3 years [5].
Minsky [7] has reported a 3-year actuarial survival of
30% and median survival of 20 months. He treated 38
patients with neoadjuvant chemotherapy followed by
concurrent chemo-radioterapy and reached the rate of
47% of complete remission after therapy. It is worth
stressing that only 34% of patients in his group were
diagnosed with T3 tumours. The local/regional failure
rate in that trial amounted to 39%.
In another RTOG trial [10] median survival was 11
months with a 2-year survival of 31%.
3-year actuarial survival as reported by Calais [14]
equalled 27%, with a local control rate of 57%. Local or
regional failure was noted in 43% of patients, with median
time to local failure of 8 months and median time to
distant metastases of 11 months. A closer look at the
stratification of patient data reveals that among the 53
patients treated only 55% presented with a T3/T4 tumour.
In a prospective phase III radiotherapy dose-
escalation study by Minsky [8] local failure and
persistence of disease exceeded 50%, with 2-year survival
of 31% and 40%, respectively, in the two treatment arms
(total dose of 50.4 Gy vs 64.8 Gy in 1.8 Gy per fraction).
In this randomised trial 44% and 49% of patients,
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respectively, out of the 109 treated in each arm presented
with T3/T4 tumours.
Gill [18] has observed complete remission in 50%
of patients after treatment. Similarly, Chan [16] achieved
local control in 68%. In his material stage III disease was
diagnosed in only 30% of patients and there were no T4
tumours. The 2-year survival for this subgroup was 25%.
In a study performed by Coia [17] 25/102 (25%)
patients presented with local control over 1 year. This
result is similar to ours. Coia reported comparable
improvement in the swallowing function for palliative as
for curative cases in his study, with a median survival
time of 8 months.
In an RTOG trial [10], where BRT treatment was
applied after external beam irradiation, a local/regional
failure rate of 63% was observed; oesophageal stricture
was found in 10% of cases with the crude fistula rate of
12%, and the cumulative fistula incidence by the end of
the first year of 17.5%. These results are also similar to
those observed in our study group.
Patients with advanced T3/T4 tumours are generally
referred for palliative treatment. Those in better general
condition are included in trials and pooled with less
advanced cases. The results of our study, performed on
a patient group with T3/T4 tumours, indicate that in case
of patients not eligible for surgery, combined non-surgical
treatment with radical intent can provide substantial
improvement in dysphagia in over half of advanced
oesophageal cancer patients and in 26% of them it results
in complete tumour regression and normal long-term
swallowing function. In case of patients with a good
performance status, in whom local disease is too advanced
to be referred for surgery, an attempt to administer
a prolonged course of combined concurrent primary
chemo-radiotherapy seems justifiable.
Conclusions
1. Primary concurrent chemo-radiotherapy for advanced
T3/T4 N0-1 scc of the oesophagus seems to be
a reasonable modality to control short- and long-term
dysphagia and pain.
2. The rate and degree of initial improvement in
swallowing function is a good prognostic tool for the
assessment of long-term swallowing status.
3. Relatively low local control rate of 26%, due to
advanced stage of the disease in our patients, indicates
the need for further evaluation of more efficient
treatment modality in this poor prognostic cancer.
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